Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma

Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years. Median duration of survival from diagnosis of MDS/AML was 10 months and six patients died. The crude incidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Saso, R, Kulkarni, S, Mitchell, P, Treleaven, J, Swansbury, G J, Mehta, J, Powles, R, Ashley, S, Kuan, R, Powles, T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374543/
https://www.ncbi.nlm.nih.gov/pubmed/10883674
http://dx.doi.org/10.1054/bjoc.2000.1196
_version_ 1782154478553661440
author Saso, R
Kulkarni, S
Mitchell, P
Treleaven, J
Swansbury, G J
Mehta, J
Powles, R
Ashley, S
Kuan, R
Powles, T
author_facet Saso, R
Kulkarni, S
Mitchell, P
Treleaven, J
Swansbury, G J
Mehta, J
Powles, R
Ashley, S
Kuan, R
Powles, T
author_sort Saso, R
collection PubMed
description Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years. Median duration of survival from diagnosis of MDS/AML was 10 months and six patients died. The crude incidence of developing MDS/AML after MMM or MM chemotherapy was 15 per 100 000 patient years follow-up, while the actuarial risk was 1.1% and 1.6% at 5 and 10 years respectively. MTZ-based regimens carry a 10 × higher risk of subsequent MDS/AML compared to that seen in the general population. © 2000 Cancer Research Campaign
format Text
id pubmed-2374543
institution National Center for Biotechnology Information
language English
publishDate 2000
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23745432009-09-10 Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma Saso, R Kulkarni, S Mitchell, P Treleaven, J Swansbury, G J Mehta, J Powles, R Ashley, S Kuan, R Powles, T Br J Cancer Regular Article Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years. Median duration of survival from diagnosis of MDS/AML was 10 months and six patients died. The crude incidence of developing MDS/AML after MMM or MM chemotherapy was 15 per 100 000 patient years follow-up, while the actuarial risk was 1.1% and 1.6% at 5 and 10 years respectively. MTZ-based regimens carry a 10 × higher risk of subsequent MDS/AML compared to that seen in the general population. © 2000 Cancer Research Campaign Nature Publishing Group 2000-07 2000-06-02 /pmc/articles/PMC2374543/ /pubmed/10883674 http://dx.doi.org/10.1054/bjoc.2000.1196 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Saso, R
Kulkarni, S
Mitchell, P
Treleaven, J
Swansbury, G J
Mehta, J
Powles, R
Ashley, S
Kuan, R
Powles, T
Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma
title Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma
title_full Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma
title_fullStr Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma
title_full_unstemmed Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma
title_short Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma
title_sort secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374543/
https://www.ncbi.nlm.nih.gov/pubmed/10883674
http://dx.doi.org/10.1054/bjoc.2000.1196
work_keys_str_mv AT sasor secondarymyelodysplasticsyndromeacutemyeloidleukaemiafollowingmitoxantronebasedtherapyforbreastcarcinoma
AT kulkarnis secondarymyelodysplasticsyndromeacutemyeloidleukaemiafollowingmitoxantronebasedtherapyforbreastcarcinoma
AT mitchellp secondarymyelodysplasticsyndromeacutemyeloidleukaemiafollowingmitoxantronebasedtherapyforbreastcarcinoma
AT treleavenj secondarymyelodysplasticsyndromeacutemyeloidleukaemiafollowingmitoxantronebasedtherapyforbreastcarcinoma
AT swansburygj secondarymyelodysplasticsyndromeacutemyeloidleukaemiafollowingmitoxantronebasedtherapyforbreastcarcinoma
AT mehtaj secondarymyelodysplasticsyndromeacutemyeloidleukaemiafollowingmitoxantronebasedtherapyforbreastcarcinoma
AT powlesr secondarymyelodysplasticsyndromeacutemyeloidleukaemiafollowingmitoxantronebasedtherapyforbreastcarcinoma
AT ashleys secondarymyelodysplasticsyndromeacutemyeloidleukaemiafollowingmitoxantronebasedtherapyforbreastcarcinoma
AT kuanr secondarymyelodysplasticsyndromeacutemyeloidleukaemiafollowingmitoxantronebasedtherapyforbreastcarcinoma
AT powlest secondarymyelodysplasticsyndromeacutemyeloidleukaemiafollowingmitoxantronebasedtherapyforbreastcarcinoma

Ejemplares similares